非小细胞肺癌术后EGFR-TKI靶向辅助治疗的临床研究进展

摘要

肺癌是目前当今世界上对人类生命危害最大的恶性肿瘤,其中非小细胞肺癌(NSCLC)占85％以上,大约20％～25％的NSCLC患者可以接受以根治为目的的外科手术.以顺铂为基础的辅助化疗是Ⅱ～Ⅲa期NSCLC完全切除术后的标准治疗方案,但其有效率低、不良反应常难以耐受.晚期NSCLC伴EGFR突变阳性患者使用表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)靶向治疗的疗效确切.近年来,关于早中期NSCLC术后伴EGFR突变阳性辅助EGFR-TKIs治疗的研究结果不断公布,肺癌术后辅助EGFR-TKIs治疗可提高疗效并改善生活质量,但目前仍有所争议.本文拟对近年来国内外关于早中期NSCLC术后辅助EGFR-TKIs靶向药物治疗的疗效和安全性作一综述.%Nowadays, lung cancer is currently the most malignant tumor to human life worldwide.Non-small cell lung cancer (NSCLC) accounts for more than 85％of lung cancer, and about 20％-25％of NSCLC patients can receive radical surgery.Cisplatin based adjuvant chemotherapy is the standard treatment for complete resection of stageⅡ-Ⅲa NSCLC, but its efficiency is low and adverse reactions are often intolerable.Targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is effective for advanced NSCLC patients with EGFR mutation.Recently, the results of adjuvant EGFR-TKIs therapy with positive EGFR mutation after early and mid-term NSCLC surgery have been published continuously.The adjuvant EGFR-TKIs treatment after lung cancer surgery can improve the efficacy and quality of life, but there is still some controversy.This article reviews the efficacy and safety of EGFR-TKIs targeted drug therapy in early and mid-term NSCLC surgery at home and abroad in recent years.